RxDoctor Payments Data

Noah Kolb, MD

Neurology · Burlington, VTNPI 1427217264

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,210 of the $21,888 with a category attached, or 74.1%. Argenx US, Inc. accounts for 73.9% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $17,588, 6.9 times the $2,550 reported in 2020.

$21,888in general payments, 2019–2025

Across 29 payments — averaging $754.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$16K
  • AstraZeneca$3K
  • Catalyst Pharmaceuticals, Inc.$2K
  • UCB, Inc.$1K
$8,513in research payments, 2019–2025

Across 2 payments — averaging $4256.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

What the payments were for

  • Consulting fees$16,21074%
  • Speaking & faculty fees$1,7508%
  • Travel & lodging$3,26915%
  • Food & beverage$6593%

General payments by program year

20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.26$16,178
AstraZeneca1$2,550
Catalyst Pharmaceuticals, Inc.1$1,750
UCB, Inc.1$1,410

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,888 in reported general payments places this provider in the 85th percentile of 41 neurology providers in Vermont.

See all neurology providers in Vermont

Medicare billing

Part B allowed, 2024
$39,373
Medicare patients
199
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZilbrysqZilucoplan Sodium11$321,651
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$98,762
Mexiletine Hcl27$3,316
Pyridostigmine Bromide60$2,937
Gabapentin110$2,663
Zolpidem Tartrate ErZolpidem Tartrate16$1,915
Duloxetine Hcl73$1,526
Pregabalin26$974
Lidocaine14$923
Azathioprine13$533
Prednisone45$267
Acetazolamide12$178
Oxcarbazepine14$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Zilbrysq$1,410$321,65111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 neurology providers in Vermont.

Other neurology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →